• IRX-616a Phase 1 dosing completed successfully with no SAEs
• Site evaluation visits for IRX-211 Phase 2 at two additional sites
• SRX-25 development planning advanced with IP strategy
• Funding facility cancellation by LFO
• Company received $490k in RDTI proceeds

Nexalis Therapeutics Ltd (ASX: NX1) reports its quarterly activities for the quarter ended 30 June 2026. Key highlights include the completion of IRX-616a Phase 1 dosing with no serious adverse events, site evaluation visits for IRX-211 Phase 2 at two additional sites, and advancements in SRX-25 development planning. The company faced a setback with the cancellation of its funding facility by Linlithgow Family Office (LFO), prompting a review of clinical development strategies. Additionally, Nexalis received $490k in Research & Development Tax Incentive (RDTI) proceeds. The company is currently assessing clinical development priorities and exploring alternative funding options to ensure continuity of its clinical trial programs.

Nexalis is focused on identifying funding options, establishing clinical development priorities, and planning efficient execution of clinical trial programs.